Correction to: Biologic disease modifying antirheumatic drugs and Janus kinase inhibitors in paediatric rheumatology – what we know and what we do not know from randomized controlled trials

Overview of attention for article published in Pediatric Rheumatology, August 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (61st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

policy: 1 policy source

Readers on

mendeley: 5 Mendeley

Summary Policy documents

So far, Altmetric has seen 1 policy document that references this research output.

Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveitis

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Mar 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.